This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why
by Zacks Equity Research
C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.
DVAXNegative Net Change MRKPositive Net Change PBYIPositive Net Change CCCCPositive Net Change
biotechs
BEAM Stock Rallies More Than 25% in 3 Months: What Next?
by Zacks Equity Research
BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.
DVAXNegative Net Change BEAMNegative Net Change PBYIPositive Net Change TRDANegative Net Change
biotechs
Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results
by Zacks Equity Research
Anavex (AVXL) falls 35% on mixed results from the mid to late-stage study of 30 mg ANAVEX2-73 for the treatment of pediatric Rett Syndrome patients aged 5-17 years.
PBYIPositive Net Change ADMANegative Net Change ACADNegative Net Change AVXLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
by Zacks Equity Research
Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.
PBYIPositive Net Change ADMANegative Net Change XENEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top 5 Momentum Picks for January After a Fabulous 2023
by Nalak Das
We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
REGNPositive Net Change SPLKPositive Net Change CASYNegative Net Change SHOPNegative Net Change BGNEPositive Net Change
biotechs internet retail
Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why
by Zacks Equity Research
Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.
VRTXNegative Net Change EDITNegative Net Change CRSPNegative Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.
PBYIPositive Net Change ADMANegative Net Change ACADNegative Net Change AXSMNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?
by Zacks Equity Research
Bayer (BAYRY) faced challenges in 2023 as sales declined in the Crop Science division. Pipeline setbacks also weighed on the stock.
REGNPositive Net Change DVAXNegative Net Change BAYRYPositive Net Change TRDANegative Net Change
biotechs pharmaceuticals
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
by Zacks Equity Research
Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.
FOLDNegative Net Change TAROPositive Net Change PBYIPositive Net Change TRDANegative Net Change
biotechs
Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Sarepta (SRPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
SRPTNegative Net Change
biotechs medical
How Vistagen (VTGN) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Vistagen (VTGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
VTGNPositive Net Change
biotechs medical
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
by Zacks Equity Research
Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.
TAROPositive Net Change PBYIPositive Net Change IOVANo Net Change TRDANegative Net Change
biotechs
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
by Zacks Equity Research
The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.
AMGNPositive Net Change PBYIPositive Net Change CHRSNegative Net Change TRDANegative Net Change
biotechs
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals
by Zacks Equity Research
Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.
BMYPositive Net Change CYTKNegative Net Change PBYIPositive Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
by Ekta Bagri
Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.
BMYPositive Net Change AMGNPositive Net Change CYTKNegative Net Change
biotechnology biotechs
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
by Zacks Equity Research
Milestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT.
AGENNegative Net Change PBYIPositive Net Change ADMANegative Net Change MISTPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
by Zacks Equity Research
Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
BMYPositive Net Change AMGNPositive Net Change MRTXPositive Net Change GLPGNegative Net Change
biotechs medical pharmaceuticals
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
by Sundeep Ganoria
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.
ALLONegative Net Change ARQTPositive Net Change CCCCPositive Net Change
biotechs immuno-therapy medical pharmaceuticals
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.
BMYPositive Net Change MRTXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
5 Leveraged ETFs That Are Up More Than 50% in December
by Sweta Killa
The demand for leveraged ETFs have increased as investors seek to register big gains in a short span.
LABUNegative Net Change DPSTNegative Net Change NAILNegative Net Change CONLNegative Net Change CARUNegative Net Change
auto-tires-trucks biotechs etfs finance
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
by Zacks Equity Research
Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
RHHBYNegative Net Change NVOPositive Net Change SRPTNegative Net Change GLPGNegative Net Change
biotechs gene-therapy medical pharmaceuticals
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
by Zacks Equity Research
The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.
TAROPositive Net Change PBYIPositive Net Change TRDANegative Net Change SNTINegative Net Change
biotechs
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.
BMYPositive Net Change ABBVPositive Net Change CEREPositive Net Change
biotechs medical pharmaceuticals
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
by Zacks Equity Research
Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.
TAROPositive Net Change PBYIPositive Net Change CDTXPositive Net Change TRDANegative Net Change
biotechs
Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag
by Zacks Equity Research
Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.
MRKPositive Net Change AGENNegative Net Change PBYIPositive Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals